> Detailanzeige

Stumpf, Julian; Anders, Leona; Siepmann, Torsten; Schwöbel, Jörg; Karger, Claudia; Lindner, Tom H; Faulhaber-Walter, Robert; Pietzonka, Annegret; Langer, Torsten; Escher, Katja; Anding-Rost, Kirsten; Seidel, Harald; Hüther, Jan; Pistrosch, Frank; Martin, Heike; Schewe, Jens; Stehr, Thomas; Meistring, Frank; Paliege, Alexander; Schneider, Daniel; Bast, Ingolf; Steglich, Anne; Gembardt, Florian; Kessel, Friederike; [...]

#5093 DIALYSIS PATIENTS AND BNT162B2MRNA VACCINE TYPE ARE RISK FACTORS FOR IMMUNITY FADING 9 MONTHS AFTER SARS-COV-2MRNA VACCINATION (DIA-VACC STUDY)

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: #5093 DIALYSIS PATIENTS AND BNT162B2MRNA VACCINE TYPE ARE RISK FACTORS FOR IMMUNITY FADING 9 MONTHS AFTER SARS-COV-2MRNA VACCINATION (DIA-VACC STUDY)
  • Beteiligte: Stumpf, Julian; Anders, Leona; Siepmann, Torsten; Schwöbel, Jörg; Karger, Claudia; Lindner, Tom H; Faulhaber-Walter, Robert; Pietzonka, Annegret; Langer, Torsten; Escher, Katja; Anding-Rost, Kirsten; Seidel, Harald; Hüther, Jan; Pistrosch, Frank; Martin, Heike; Schewe, Jens; Stehr, Thomas; Meistring, Frank; Paliege, Alexander; Schneider, Daniel; Bast, Ingolf; Steglich, Anne; Gembardt, Florian; Kessel, Friederike; [...]
  • Erschienen: Oxford University Press (OUP), 2023
  • Erschienen in: Nephrology Dialysis Transplantation
  • Sprache: Englisch
  • DOI: 10.1093/ndt/gfad063c_5093
  • ISSN: 1460-2385; 0931-0509
  • Schlagwörter: Transplantation ; Nephrology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background and Aims</jats:title> <jats:p>SARS-CoV-2mRNA vaccination related seroconversion rates are reduced in dialysis (DP) and kidney transplant patients (KTR). Recently, we demonstrated that established vaccination related immunity (via positive seroconversion) fades faster in DP and at a lesser extent in KTR compared to medical personnel (MP).[1] We hypothesized that a longer follow up period might be able to profoundly show immunity fading differences specific to different patient groups and identify strong fading risk factors that are relevant for patient management especially in vulnerable groups.</jats:p> </jats:sec> <jats:sec> <jats:title>Method</jats:title> <jats:p>We evaluated nine months follow up data in our observational Dia-Vacc study exploring specific cellular (interferon-γ release assay) or/and humoral immune responses after 2x SARS-CoV-2mRNA vaccination in 880 participants including healthy MP (125), DP (595), KTR (111), and apheresis patients (49-AP) with positive seroconversion (de novo IgA or IgG antibody positivity by ELISA) after eight weeks.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Nine months after first vaccination, receptor binding domain (RBD) antibodies were still positive in 90 % of MP, 86 % of AP, but only 55 %/48 % of DP/KTR, respectively. Seroconversion remained positive in 100 % of AP and 99·2 % of MP, but 86 %/81 % of DP/KTR, respectively. Compared to MP, DP but not KTR or AP were at risk for a strong RBD decline, while KTR kept lowest RBD values over time (see Fig. 1 and Table 1). By multivariate analysis, BNT162b2mRNA versus 1273-mRNA vaccine type was an independent risk factor for a strong decline of RBD antibodies. Within the DP group, only time on dialysis was another (inverse) risk factor for the DP group. Compared to humoral immunity, T-cell immunity decline was less prominent.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>While seroconverted KTR reach lowest RBD values over time, DP are at specific risk for a strong decline of RBD antibodies after successful SARS-CoV-2mRNA vaccination, which also depends on the vaccine type being used. Therefore, booster vaccinations for DP should be considered earlier compared to normal population.</jats:p> </jats:sec>